Mary Browning
Physician Assistant · Gainesville, FLNPI 1144740283
Payments from drug & device makers
Across 117 payments — averaging $158.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$17K
- AbbVie$603
- Tris Pharma Inc$343
- AstraZeneca$117
- Gilead$113
- Neurocrine Biosciences, Inc.$109
- plus $646 from 12 others
What the payments were for
- Speaking & faculty fees$11,45062%
- Travel & lodging$3,40618%
- Food & beverage$3,66620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 62 | $16,591 |
| AbbVie | 20 | $603 |
| Tris Pharma Inc | 8 | $343 |
| AstraZeneca | 1 | $117 |
| Gilead | 1 | $113 |
| Neurocrine Biosciences, Inc. | 1 | $109 |
| UCB, Inc. | 1 | $98 |
| CSL Behring | 1 | $97 |
| Biofire Diagnostics, LLC | 2 | $72 |
| Biomerieux Inc | 2 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $67 |
| Pfizer | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Ironshore Pharmaceuticals Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$15,465
- VRAYLAR$467
- Dyanavel XR$118
- Quillivant$118
- Quillichew ER$118
- Epclusa$113
How this compares
$18,522 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $20,423 |
| SpravatoEsketamine Hcl | 11 | $18,491 |
| Quetiapine Fumarate | 53 | $925 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $835 |
| Temazepam | 11 | $726 |
| Hydroxyzine Hcl | 33 | $697 |
| Prazosin Hcl | 22 | $357 |
| Bupropion Hcl SrBupropion Hcl | 11 | $309 |
| Mirtazapine | 22 | $304 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $289 |
| Aripiprazole | 15 | $257 |
| Gabapentin | 15 | $226 |
| Bupropion XlBupropion Hcl | 14 | $224 |
| Trazodone Hcl | 54 | $175 |
| Clonazepam | 33 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $21 | $20,42312 claims |
| Johnson & JohnsonSpravato | $16,591 | $18,49111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Gainesville
- Ashley MillerGainesville$328K
- Mary Kate VellisGainesville$79K
- Kelsey KimballGainesville$41K
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.